Auron Therapeutics
Biotechnology company developing transformative therapies targeting dysregulated differentiation and cellular plasticity for treating cancer by restoring normal cell differentiation programs.
Website
https://www.aurontx.comLocation
New York, New York, USA
Founded
2019
Investors
1
Categories
biotech, oncology, therapeutics, transcription-factors, precision-medicine
Notes
Auron Therapeutics is a biotechnology company focused on precision oncology through a differentiation-focused approach. The company is developing therapeutics that target transcription factors and cellular differentiation pathways that are dysregulated in cancer, aiming to reprogram cancer cells back to a normal differentiated state.
In February 2025, Auron announced FDA clearance for its lead program and closed a $27 million Series B funding round.
Team
- Anand Patel, Ph.D. - Co-Founder and CEO
- Scott Armstrong, M.D., Ph.D. - Co-Founder and Scientific Advisor (Professor at Harvard Medical School, Dana-Farber Cancer Institute)
- Christopher Vakoc, M.D., Ph.D. - Co-Founder and Scientific Advisor (Professor at Cold Spring Harbor Laboratory)
Additional Research Findings
- Raised $27 million in Series B (February 2025)
- Backed by Apollo Health Ventures
- FDA clearance announced for lead program
- Focus on transcription factor-targeted cancer therapy
- Targeting dysregulated differentiation and cellular plasticity
- Scientific founders from Dana-Farber and Cold Spring Harbor Laboratory
- Novel approach to reprogram cancer cells to normal differentiated state
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apollo Health Ventures | Dusseldorf, Germany / Boston, USA | biotech-focused | seedseries-a+1 | 15 |